Histone Deacetylase Inhibitors

"Histone Deacetylase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Compounds that inhibit HISTONE DEACETYLASES. This class of drugs may influence gene expression by increasing the level of acetylated HISTONES in specific CHROMATIN domains.

Descriptor ID	D056572
MeSH Number(s)	D27.505.519.389.360
Concept/Terms	Histone Deacetylase Inhibitors Histone Deacetylase Inhibitors Deacetylase Inhibitors, Histone Inhibitors, Histone Deacetylase Histone Deacetylase Inhibitor Deacetylase Inhibitor, Histone Inhibitor, Histone Deacetylase HDAC Inhibitors Inhibitors, HDAC

Below are MeSH descriptors whose meaning is more general than "Histone Deacetylase Inhibitors".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Molecular Mechanisms of Pharmacological Action [D27.505.519]
Enzyme Inhibitors [D27.505.519.389]
Histone Deacetylase Inhibitors [D27.505.519.389.360]

Below are MeSH descriptors whose meaning is related to "Histone Deacetylase Inhibitors".

Below are MeSH descriptors whose meaning is more specific than "Histone Deacetylase Inhibitors".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Histone Deacetylase Inhibitors" by people in this website by year, and whether "Histone Deacetylase Inhibitors" was a major or minor topic of these publications.

Bar chart showing 22 publications over 15 distinct years, with a maximum of 3 publications in 2008 and 2010

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2000	0	1	1
2002	0	1	1
2003	1	0	1
2008	3	0	3
2010	3	0	3
2011	1	0	1
2012	2	0	2
2013	2	0	2
2014	0	1	1
2015	0	1	1
2016	1	0	1
2018	1	1	2
2019	0	1	1
2021	1	0	1
2022	0	1	1

Below are the most recent publications written about "Histone Deacetylase Inhibitors" by people in Profiles.

Khvorova A. Modulation of DNA transcription: The future of ASO therapeutics? Cell. 2022 06 09; 185(12):2011-2013.

View in: PubMed
Chaudhuri S, Fowler MJ, Baker C, Stopka SA, Regan MS, Sablatura L, Broughton CW, Knight BE, Stabenfeldt SE, Agar NYR, Sirianni RW. ?-Cyclodextrin-poly (?-Amino Ester) Nanoparticles Are a Generalizable Strategy for High Loading and Sustained Release of HDAC Inhibitors. ACS Appl Mater Interfaces. 2021 May 12; 13(18):20960-20973.

View in: PubMed
Zhao P, Wang H, Wang H, Dang Y, Luo L, Li S, Shi Y, Wang L, Wang S, Mager J, Zhang K. Essential roles of HDAC1 and 2 in lineage development and genome-wide DNA methylation during mouse preimplantation development. Epigenetics. 2020 04; 15(4):369-385.

View in: PubMed
Krajewski D, Kaczenski E, Rovatti J, Polukort S, Thompson C, Dollard C, Ser-Dolansky J, Schneider SS, Kinney SRM, Mathias CB. Epigenetic Regulation via Altered Histone Acetylation Results in Suppression of Mast Cell Function and Mast Cell-Mediated Food Allergic Responses. Front Immunol. 2018; 9:2414.

View in: PubMed
Das A, Henderson F, Lowe S, Wallace GC, Vandergrift WA, Lindhorst SM, Varma AK, Infinger LK, Giglio P, Banik NL, Patel SJ, Cachia D. Single agent efficacy of the HDAC inhibitor DATS in preclinical models of glioblastoma. Cancer Chemother Pharmacol. 2018 12; 82(6):945-952.

View in: PubMed
Almeida S, Gao F, Coppola G, Gao FB. Suberoylanilide hydroxamic acid increases progranulin production in iPSC-derived cortical neurons of frontotemporal dementia patients. Neurobiol Aging. 2016 06; 42:35-40.

View in: PubMed
Ruscetti M, Dadashian EL, Guo W, Quach B, Mulholland DJ, Park JW, Tran LM, Kobayashi N, Bianchi-Frias D, Xing Y, Nelson PS, Wu H. HDAC inhibition impedes epithelial-mesenchymal plasticity and suppresses metastatic, castration-resistant prostate cancer. Oncogene. 2016 07 21; 35(29):3781-95.

View in: PubMed
Gordon JAR, Stein JL, Westendorf JJ, van Wijnen AJ. Chromatin modifiers and histone modifications in bone formation, regeneration, and therapeutic intervention for bone-related disease. Bone. 2015 Dec; 81:739-745.

View in: PubMed
Dudakovic A, Camilleri ET, Lewallen EA, McGee-Lawrence ME, Riester SM, Kakar S, Montecino M, Stein GS, Ryoo HM, Dietz AB, Westendorf JJ, van Wijnen AJ. Histone deacetylase inhibition destabilizes the multi-potent state of uncommitted adipose-derived mesenchymal stromal cells. J Cell Physiol. 2015 Jan; 230(1):52-62.

View in: PubMed
Usmani SZ, Lonial S. Novel drug combinations for the management of relapsed/refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2014 Sep; 14 Suppl:S71-7.

View in: PubMed

People

Explore

Similar Concepts

Top Journals